China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List
PR Newswire Asia
SUZHOU, China, and ROCKVILLE, MD, Jan. 19, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company..